Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Natan Ponieman

EXCLUSIVE: Bexson Biomedical Inks Agreement With Stevanato For Delivery System Of Ketamine In Pain Management

Bexson Biomedical, a private company in the psychedelics space, has inked a new agreement with Stevanato Group, an Italian-based provider of drug delivery solutions.

Bexson is currently developing an improved version of ketamine called BB106, which allows for subcutaneous delivery of the drug. The company received a patent from the USPTO for this formulation in 2021.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.